bafiertam Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Bafiertam, and what generic alternatives are available?
Bafiertam is a drug marketed by Banner Life Sciences and is included in one NDA. There are twenty-one patents protecting this drug.
This drug has twenty patent family members in seven countries.
The generic ingredient in BAFIERTAM is monomethyl fumarate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the monomethyl fumarate profile page.
DrugPatentWatch® Generic Entry Outlook for Bafiertam
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be August 10, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for bafiertam
International Patents: | 20 |
US Patents: | 21 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 102 |
Clinical Trials: | 3 |
Patent Applications: | 1,464 |
Drug Prices: | Drug price information for bafiertam |
What excipients (inactive ingredients) are in bafiertam? | bafiertam excipients list |
DailyMed Link: | bafiertam at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for bafiertam
Generic Entry Date for bafiertam*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE, DELAYED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for bafiertam
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Banner Life Sciences LLC | Phase 1 |
US Patents and Regulatory Information for bafiertam
bafiertam is protected by twenty-one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of bafiertam is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting bafiertam
Fumarate esters
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING MULTIPLE SCLEROSIS
Fumarate ester dosage forms
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Fumarate ester pharmaceutical compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING MULTIPLE SCLEROSIS
Fumarate ester pharmaceutical compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING MULTIPLE SCLEROSIS
Fumarate ester pharmaceutical compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING MULTIPLE SCLEROSIS
Fumarate ester pharmaceutical compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING MULTIPLE SCLEROSIS
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING MULTIPLE SCLEROSIS
Controlled release fumarate esters
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Controlled release fumarate esters
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING MULTIPLE SCLEROSIS
Fumarate ester pharmaceutical compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING MULTIPLE SCLEROSIS
Fumarate ester pharmaceutical compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Fumarate ester dosage forms
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Fumarate ester dosage forms
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING MULTIPLE SCLEROSIS
Fumarate ester dosage forms
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Fumarate ester pharmaceutical compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING MULTIPLE SCLEROSIS
Fumarate ester dosage forms
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING MULTIPLE SCLEROSIS
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Fumarate ester dosage forms
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: METHOD OF TREATING MULTIPLE SCLEROSIS
International Patents for bafiertam
When does loss-of-exclusivity occur for bafiertam?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 15222880
Estimated Expiration: ⤷ Try a Trial
Patent: 15328676
Estimated Expiration: ⤷ Try a Trial
Patent: 16253548
Estimated Expiration: ⤷ Try a Trial
Patent: 17204505
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 39990
Estimated Expiration: ⤷ Try a Trial
Patent: 62916
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 10408
Estimated Expiration: ⤷ Try a Trial
Patent: 01510
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 10408
Estimated Expiration: ⤷ Try a Trial
Patent: 01510
Estimated Expiration: ⤷ Try a Trial
Patent: 66487
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 7326
Estimated Expiration: ⤷ Try a Trial
Patent: 5752
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 13157
Estimated Expiration: ⤷ Try a Trial
Patent: 17584
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering bafiertam around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 3766487 | CAPSULES ENTÉRIQUES MOLLES À LIBÉRATION CONTRÔLÉE D'ESTERS DE FUMARATE (CONTROLLED RELEASE ENTERIC SOFT CAPSULES OF FUMARATE ESTERS) | ⤷ Try a Trial |
Denmark | 3501510 | ⤷ Try a Trial | |
Denmark | 3110408 | ⤷ Try a Trial | |
World Intellectual Property Organization (WIPO) | 2016057133 | ⤷ Try a Trial | |
Canada | 2939990 | CAPSULES MOLLES ENTERIQUES A LIBERATION CONTROLEE D'ESTERS DE FUMARATE (CONTROLLED RELEASE ENTERIC SOFT CAPSULES OF FUMARATE ESTERS) | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2017040272 | ⤷ Try a Trial | |
World Intellectual Property Organization (WIPO) | 2015130998 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |